Current position of GLP-1 receptor agonists in type 2 diabetes mellitus treatment

Czech version

Authors: Zbynek Schroner
Authors‘ workplace: Lekárska fakulta, Univerzita Pavla Jozefa Šafárika v Košiciach
Published in: Diab Obez 2024; 24(1): 53-61
Category:

Overview

In last years significant changes happened in recommendations and algorithms of national and international societies for management of treatment of type 2 diabetes mellitus. Therapy with GLP-1 receptors agonists shows various multiorgan benefits. By these guidelines GLP-1 receptor agonists have important place in therapy of type 2 diabetes. Possible reasons of preference of this treatment are: efficacy, decrease of weight, CV protectivity, slow down the progression of nephropathy, protection of function of B-cells, safety (low risk of hypoglycemia, small incidence of serious adverse events), decrease of blood pressure, lipids, biomarkers of CV risk, markers of chronic subclinical inflammation.

Keywords:

therapeutic place – type 2 diabetes mellitus – GLP-1 receptor agonists

Sources

Davies MJ, Aroda VR, Collins BS et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022; 45(11): 2753–2786. Dostupné z DOI: <http://dx.doi.org/10.2337/dci22–0034>.

Marx N, Federici M, Schut K et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023; 44(39): 4043–4140. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehad192>.

Martinka E, Tkáč I, Mokáň M et al. Odporúčané postupy pre liečbu diabetes mellitus 2. Typu – 2023. Forum Diab 2023; 12(2): 93–133.

Bays HE, Taub PR, Epsstein E et al. Ten things to know about ten cardiovascular disease risk factors. Am J Prev Cardiol 2021; 5: 100149. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ajpc.2021.100149>.

Mosenzon O, Alguwaihes A, Leon LJA et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol 2021; 20(1):154. Dostupné z DOI: <https://doi.org/10.1186/s12933–021–01344–0>.

Poznyak A, Grechko AV, Poggio P et al. The Diabetes Mellitus-Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci 2020; 21(5): 1835. Dostupné z DOI: <http://dx.doi.org/10.3390/ijms21051835>.

Sattar N, Lee MMY, Kristensen SL et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9(10): 653–662. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(21)00203–5>.

Marsico F, Paolillo S, Gargiuolo P et al. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Euro Heart J 2020; 41(35): 3346–3358. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehaa082>.

Nauck MA, Quast DR, Wefers J et al. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab 2021; 23(Suppl 3): 5–29. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.14496>.

Visseren FLJ, Mach F, Smulders YM et al. [ESC National Cardiac Societies; ESC Scientific Document Group]. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42(34): 3227–3337. Dostupné z DOI: https://doi: <10.1093/eurheartj/ehab484>.